Allergen-related approaches to immunotherapy

Rolland, Jennifer M.; Gardner, Leanne Margaret; O’Hehir, Robyn E

doi:10.1016/j.pharmthera.2008.11.007

Cited by 73 publications

(79 citation statements)

References 191 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, discovery of allergen-specific immunotherapy raised a number of crucial questions regarding the route of administration, the dose response relationship, and the intervals between administrations [30]. Nowadays, several immunotherapeutic strategies have been achieved to modulate the immune system by different pathways [13]. Advances in the standardization of allergenic composition of vaccines, optimal dose of allergen and, above all, clinical studies that support their effectiveness are crucial not only to achieve more effective and safe vaccines, but also to provide greater dosing convenience [31].…”

Section: Allergen-specific Immunotherapymentioning

confidence: 99%

“…Since the first description of allergy in early 1900s, significant progress to research and clinics has been made in offer possible innovative therapeutics for the management of allergic diseases [10][11][12][13]. Remarkable advances in allergen immunotherapy include the use of purified allergens-based vaccines [14], blocking antibodies [15], the recombinant interleukins administration [16,17], DNA vaccines [18], and gene therapy [19].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Genetic toxicology and preliminaryin vivostudies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents

Cabrera

López

Gómez

et al. 2011

Drug and Chemical Toxicology

View full text Add to dashboard Cite

In the last decades, significant progress in research and clinics has been made to offer possible innovative therapeutics for the management of allergic diseases. However, current allergen immunotherapy shows limitations concerning the long-term efficacy and safety due to local side effects and risk of anaphylaxis. Thus, effective and safe vaccines with reduced dose of allergen have been developed using adjuvants. Nevertheless, the use of adjuvants still has several disadvantages, which limits its use in human vaccines. In this context, several novel adjuvants for allergen immunotherapy are currently being investigated and developed. Currently, nanoparticles-based allergen-delivery systems have received much interest as potential adjuvants for allergen immunotherapy. It has been demonstrated that the incorporation of allergens into a delivery system plays an important role in the efficacy of allergy vaccines. Several nanoparticles-based delivery systems have been described, including biodegradable and nondegradable polymeric carriers. Therefore, this paper provides an overview of the current adjuvants used for allergen immunotherapy. Furthermore, nanoparticles-based allergen-delivery systems are focused as a novel and promising strategy for allergy vaccines.

show abstract

Section: Allergen-specific Immunotherapymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Genetic toxicology and preliminaryin vivostudies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents

Cabrera

López

Gómez

et al. 2011

Drug and Chemical Toxicology

View full text Add to dashboard Cite

show abstract

“…Traditionally, vaccines generate a robust immune response to a particular antigen by adsorbing the antigen to an alum particle surface (3)(4)(5). Though individual alum particles are quite small (10-50 nm), in solution they form insoluble agglomerates that have a typical size range of 1-10 μm to which the antigen of interest is presented on the surface (6).…”

Section: Introductionmentioning

confidence: 99%

Structure, Size, and Solubility of Antigen Arrays Determines Efficacy in Experimental Autoimmune Encephalomyelitis

Sestak

Fakhari

Badawi

et al. 2014

AAPS J

View full text Add to dashboard Cite

ABSTRACT. Presentation of antigen with immune stimulating "signal" has been a cornerstone of vaccine design for decades. Here, the antigen plus immune "signal" of vaccines is modified to produce antigen-specific immunotherapies (antigen-SITs) that can potentially reprogram the immune response toward tolerance of an autoantigen. The codelivery of antigen with a cell adhesion inhibitor using Soluble Antigen Arrays (SAgAs) was previously shown to slow or halt experimental autoimmune encephalomyelitis (EAE), a murine form of multiple sclerosis (MS). SAgAs are comprised of a hyaluronic acid backbone with cografted intercellular cell adhesion molecule-1 ligand derived from α L -integrin (CD11a 237-246 , "LABL") and an encephalitogenic epitope peptide of proteolipid protein (PLP 139-151 , "PLP"). Here, the physical characteristics of the carrier were investigated to evaluate how structure, size, and solubility drive the immune response when treating EAE. A bifunctional peptide (small, soluble), SAgAs (large, soluble), and PLGA nanoparticles (large, insoluble) all displaying PLP and LABL in equimolar ratios were compared. Maximum EAE suppression was achieved with coincident display of both peptides on a soluble construct.

show abstract

“…Recently, the induction of regulatory T (Treg) cells has attracted much attention in terms of SIT (3,11,20). Treg cells constitutively express the interleukin-2 (IL-2) receptor chain (CD25) at high levels, and the forkhead transcription factor, forkhead box protein 3 (Foxp3), is considered essential for the development and function of Treg cells (1).…”

mentioning

confidence: 99%

Induction of Immune Tolerance in Asthmatic Mice by Vaccination with DNA Encoding an Allergen–Cytotoxic T Lymphocyte-Associated Antigen 4 Combination

Zhang

Huang

et al. 2011

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

show abstract

Allergen-related approaches to immunotherapy

Cited by 73 publications

References 191 publications

Genetic toxicology and preliminaryin vivostudies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents

Genetic toxicology and preliminaryin vivostudies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents

Structure, Size, and Solubility of Antigen Arrays Determines Efficacy in Experimental Autoimmune Encephalomyelitis

Induction of Immune Tolerance in Asthmatic Mice by Vaccination with DNA Encoding an Allergen–Cytotoxic T Lymphocyte-Associated Antigen 4 Combination

Contact Info

Product

Resources

About